通过欧洲临床测序项目确定的儿科高危恶性肿瘤的改变构成了有前景的药物靶点。 - Suppr

Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.

作者信息

Pfaff Elke, Adam de Beaumais Tiphaine, Marchais Antonin, van Tilburg Cornelis M, Blattner-Johnson Mirjam, Dirksen Uta, Øra Ingrid, Geoerger Birgit, Schleiermacher Gudrun, Pfister Stefan M, Witt Olaf, Jones David T W, Vassal Gilles

机构信息

Elke Pfaff, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Tiphaine Adam de Beaumais, MD, Clinical Research Department, Gustave Roussy Cancer Center, Villejuif, France; Antonin Marchais, PhD, Bioinformatics and INSERM U1015, Gustave Roussy Cancer Center, University Paris-Saclay, Villejuif, France; Cornelis M. van Tilburg, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany German Cancer Consortium (DKTK), Germany; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany; Mirjam Blattner-Johnson, PhD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; Uta Dirksen, MD, German Cancer Consortium (DKTK), Partner Essen, Germany; University Hospital Essen, Pediatrics III, Hematology and Oncology, West German Cancer Centre, Essen, Germany; Ingrid 00D8ra, MD, PhD, Department of Pediatric Oncology and Hematology, Karolinska University Hospital, Solna, Sweden; Skane University Hospital, Lund, Sweden; Birgit Geoerger, MD, PhD, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, INSERM U1015, University Paris-Saclay, Villejuif, France; Gudrun Schleiermacher, MD, Equipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Stefan M. Pfister, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Olaf Witt, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany; David T. W. Jones, PhD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; and Gilles Vassal, MD, PhD, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.